Category: cell biology

A PNAS expression of concern appears — and so does its revealing backstory

pnas 1113When retraction notices and expressions of concern appear, particularly those that are opaque, we try our best to find out what’s behind them, whether it’s better explanations or the steps that led to moves. Today, we have one story in which we’ve been able to learn a lot more than usual.

In April, Bas van Steensel, Wendy Bickmore, Thomas Cremer, and Kerstin Bystricky sent a letter to about 80 leading labs in nuclear organization and steroid receptor biology. It began (we’ve added some relevant links): Continue reading A PNAS expression of concern appears — and so does its revealing backstory

Scientist in Ireland notches two mysterious retractions and a correction

Sinead Miggin, via NUIM
Sinead Miggin, via NUIM

Sinead Miggin, a biologist at the National University of Ireland Maynooth, has withdrawn two papers from the Journal of Biological Chemistry (JBC) and has corrected another paper, in the Proceedings of the National Academy of Sciences (PNAS).

Here’s the opaque JBC notice for “14-3-3ϵ and 14-3-3σ inhibit Toll-like receptor (TLR)-mediated proinflammatory cytokine induction,” a paper first published in November 2012: Continue reading Scientist in Ireland notches two mysterious retractions and a correction

First author blamed for retraction in prestigious medical journal

jemcoverThe authors of a Journal of Experimental Medicine have retracted it, blaming the first author for data and figure manipulation.

The paper, “The requirements for natural Th17 cell development are distinct from those of conventional Th17 cells,” was initially published in September 2011 and has been cited 25 times, according to Thomson Scientific’s Web of Knowledge. First author Jiyeon Kim was an MD-PhD candidate at the University of Pennsylvania until this year, according to a LinkedIn profile.

Here’s the notice: Continue reading First author blamed for retraction in prestigious medical journal

New method sinks newish paper…or does it?

cover_2009_BB_viz_biomassThe timing on a recent retraction of a paper from Biotechnology and Bioengineering makes it a bit difficult to figure out what happened, but here’s a try.

An article first published online May 16th by a group of researchers at Brown University was retracted on June 1st, apparently because a new and better method for analyzing the data was developed…at some point.

The timeline is not exactly clear from the retraction, though we’ve reached out to the author and publisher and will update with any new information.

Here’s the (paywalled) notice for “High-level production of 3-hydroxypropionatein Escherichia coli and Saccharomyces cerevisiae by introducing part of the 3-hydroxypropionate/4-hydroxybutyrate cycle from Metallosphaera sedula”:

Continue reading New method sinks newish paper…or does it?

Sampling the wrong part of the aorta sinks aneurysm paper

plosoneA paper on an experimental treatment for abdominal aneurysms has been retracted after it was discovered samples had been taken from the wrong part of the aorta.

Here is the PLOS ONE notice for “Inhibition of Rho-Kinase by Fasudil Suppresses Formation and Progression of Experimental Abdominal Aortic Aneurysms:” Continue reading Sampling the wrong part of the aorta sinks aneurysm paper

University of Maryland duo notches third retraction

Anil Jaiswal, via U Maryland
Anil Jaiswal, via U Maryland

A pair of researchers at the University of Maryland have retracted a third paper.

Here’s the unhelpful Journal of Biological Chemistry notice for “Inhibitor of Nrf2 (INrf2 or Keap1) protein degrades Bcl-xL via phosphoglycerate mutase 5 and controls cellular apoptosis,” by Suryakant Niture and Anil Jaiswal: Continue reading University of Maryland duo notches third retraction

A year after ORI report, hematology journal retracts faked paper

bloodA year after an ORI report discredited the work of former University of Washington in Seattle researcher Andrew Aprikyan, one of the papers named in the report has finally been retracted.

Here’s the notice for “Impaired survival of bone marrow hematopoietic progenitor cells in cyclic neutropenia”:  Continue reading A year after ORI report, hematology journal retracts faked paper

PLOS ONE retraction notice blames deceased author for image manipulation

A 2011 paper in PLOS ONE has been retracted due to “inappropriately assembled” images. The issues, which were highlighted in a correction in TK, are attributed to the corresponding author, Paola Palozza, who has since passed away.

Here’s the notice for “Lycopene Inhibits NF-kB-Mediated IL-8 Expression and Changes Redox and PPARγ Signalling in Cigarette Smoke–Stimulated Macrophages,” which has been cited 33 times, according to Thomson Scientific’s Web of Knowledge: Continue reading PLOS ONE retraction notice blames deceased author for image manipulation

Another Nature stem cell paper is retracted

nature 73014Another stem cell paper has been retracted from Nature, this one a highly cited 2008 study that had already been the subject of what the journal’s news section called a “furore” in 2010.

According to that 2010 news story:

The researchers behind the original work1, led by Thomas Skutella of the University of Tübingen, reported using cells from adult human testes to create pluripotent stem cells with similar properties to embryonic stem cells.

But a 2010 Brief Communication Arising called those findings into question. And now, the authors have retracted the paper. Here’s the notice for “Generation of pluripotent stem cells from adult human testis:” Continue reading Another Nature stem cell paper is retracted

MD Anderson postdoc faked results of Novartis anti-cancer compound study

jun fu
Raymond Sawaya, director of MD Anderson’s brain tumor program, presents Jun Fu with the 2014 Caroline Ross Endowment Fellowship.

A former postdoc at MD Anderson Cancer Center faked the results of a mouse study of a Novartis compound designed to fight brain tumors, according to the Office of Research Integrity (ORI).

Jun Fu “admitted to knowingly and intentionally falsifying Figure 8a” in “Novel HSP90 Inhibitor NVP-HSP990 Targets Cell-Cycle Regulators to Ablate Olig2-Positive Glioma Tumor–Initiating Cells,” a paper published in Cancer Research on May 15, 2013:

Continue reading MD Anderson postdoc faked results of Novartis anti-cancer compound study